Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: February 25, 2025
Reporting Period: Fourth quarter and full year ended December 31, 2024
This filing serves as a notification that the Company issued a press release regarding its financial results for the fourth quarter and full year ended December 31, 2024. The detailed financial data is contained in Exhibit 99.1 (Press Release), which is incorporated by reference but not deemed "filed" under Section 18 of the Exchange Act.
Key Financial Metrics
The provided text is a cover document for the 8-K filing and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the referenced press release (Exhibit 99.1), which is not included in the input text.
Source data does not provide clear values for financial metrics in this specific document.
Material Changes
No specific material changes versus the prior comparable period are detailed in this text. The filing indicates that a conference call was held to present business and financial results, implying a discussion of performance trends, but the specific variances are not listed here.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions, identified by terms such as "believe," "expect," and "anticipate."
- Risk Factors: The Company directs investors to Item 1A, "Risk Factors," in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, for a comprehensive list of risks and uncertainties.
- Outlook: No specific numerical guidance or outlook figures are provided in this text.
- Unusual Items: None disclosed in this summary text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2024 revenue, net income, and cash flow figures.
- Access the archived webcast on the Company's website (www.supernus.com) for management commentary on the results.
- Consult the Form 10-K for the year ended December 31, 2023 for detailed risk factors referenced in this filing.
- Verify the Company's status as an emerging growth company (indicated as not applicable in this filing).